rais estim upsid lcd core
growth improv cdd core
earlier today publish first look lh result link
addit takeaway encourag favor test mix util
organ volum trend quarter temper bit lower margin
expect lab margin hurt pama one addit payrol day also
unexpect headwind unh non-renew beaconlbspilot program
florida start prepar launch prefer lab network
non-renew hit revenue per requisit rpr
headwind although comp get easier given weak industri trend
lh also note lab lcd margin would flat slightli in-lin
expect
given higher expect contribut envigo covanc cdd revenue
growth cdd updat guid y/i impli lower organ growth
compani face one hardest cro comp
model cdd revenue growth organ
said cdd margin continu show good gain y/i help boost
higher-margin envigo busi
tweak sale ep est reiter neutral rate
lh narrow ep outlook vs prior rais
full-year revenu growth expect
forecast sale higher lcd est
partial off-set lower cdd organ growth est ep est
overal lab trend begun stabil believ alreadi
reflect current valuat reiter neutral rate po
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
pama protect access
cdd covanc contract research
organ cro segment lh
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lh second-largest clinic laboratori
 intern invest acquisit
compani expand clinic diagnost
technolog offer better insul
growth rate lh also expand contract
research organ industri
acquisit covanc chiltern account
market share global
although see upsid potenti elev
lab consolid catalyz medicar
opportun monet lab data recent
multipl guidanc cut suggest visibl
limit said posit lh
abil weather headwind strong
industri trend drive higher growth
compani cro contract research
po base sotp analysi assum multipl lh lcd lab
segment in-lin clinic lab histor five-year median forward multipl
multipl cdd cro segment in-lin peer ev/ebitda
upsid risk faster expect materi hospit lab consolid
trend smaller expect share loss contract retail clinic opportun
monet data lab cro busi significantli faster
cro growth margin improv
downsid risk greater expect price headwind lower expect test
volum growth competit execut risk integr risk data privaci risk
regulatori risk covanc drug develop side lh like get much
credit cdd well expect given peer get
punish downsid sentiment wane segment fall short
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
